Stock REGN REGENERON PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
883.2 USD -0.84% Intraday chart for Regeneron Pharmaceuticals, Inc. -1.52% +0.56%
Apr. 26 Regeneron Faces Q1 Seasonality Despite Eylea HD Launch, Oppenheimer Says MT
Apr. 26 Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,125 MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Regeneron Faces Q1 Seasonality Despite Eylea HD Launch, Oppenheimer Says
MT
Regeneron Sets Crispr-Based Collaboration With Mammoth Biosciences
DJ
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation Crispr-Based Gene Editing for Multiple Diseases
CI
Sanofi Q1 profit slips on generic competition, forex effects
RE
Unity Biotechnology Adds More Patients, Extends Length of Trial of Prospective Macular Edema Treatment
MT
The market is pinning its hopes on earnings reports
Our Logo
Regeneron to defend against DOJ complaint on drug-price manipulation
RE
Regeneron to defend US Justice Department's complaint on drug-pricing manipulation
RE
Global markets live: Airbus, UBS, KKR, Meta Platforms, Tesla...
Our Logo
Sector Update: Health Care Stocks Steady Pre-Bell Thursday
MT
News Highlights : Top Company News of the Day - Thursday at 5 AM ET
DJ
News Highlights : Top Company News of the Day - Thursday at 3 AM ET
DJ
News Highlights : Top Company News of the Day - Thursday at 1 AM ET
DJ
News Highlights : Top Company News of the Day - Wednesday at 11 PM ET
DJ
News Highlights : Top Company News of the Day - Wednesday at 9 PM ET
DJ
US DOJ Files Complaint Against Regeneron Pharmaceuticals for Alleged Fraudulent Drug Price Reporting
MT
News Highlights : Top Company News of the Day - Wednesday at 7 PM ET
DJ
US DOJ Files Complaint Against Regeneron Pharmaceuticals for Alleged Fraudulent Drug Price Reporting
MT
US Justice department files complaint against Regeneron, alleges fraudulent drug pricing
RE
US accuses Regeneron of fraudulent price reporting for eye drug
RE
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. REGN Stock
  4. News Regeneron Pharmaceuticals, Inc.
  5. Highlights